Heart valves from Medtronic, Edwards show "encouraging" results

10/24/2011 | MassDevice.com (Boston)

A U.K. study of 877 transcatheter aortic valve implant procedures done from January 2007 to December 2009 found that patients who received Medtronic's CoreValve had lower death rates, while patients who received Edwards Lifesciences' Sapien device had reduced rates of repeat procedures and pacemaker use. Edwards anticipates FDA clearance for its device soon, while Medtronic expects its device to be available in the U.S. market by 2014.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA